Long Lab

Leveraging omics for cancer discoveries

As an interdisciplinary computational biologist, my research focuses on developing and implementing integrative computational approaches to omics data sets to reveal novel insight into cancer development and therapy resistance.

I have collaborated extensively with basic science and clinical investigators in the areas of bulk and single-cell genomics and epigenomics, including several multi-omics correlative studies utilizing clinical specimens from NIH-funded clinical trials.

Meet the PI

Mark Long, PhD

Biomedical Informatics

Dr. Long on PubMed Dr. Long on Twitter

Implementation and analysis of immunogenomics and single-cell approaches to understand the evolving tumor immune microenvironment (TIME) in cancer development and immunotherapeutic resistance

See the science

Leveraging multi-omics approaches to study determinants of lineage plasticity in cancer

Read the research

Roswell Park – University of Chicago Ovarian Cancer SPORE

The mission: Reducing the morbidity and mortality of ovarian cancer through innovative translational research
The award: Career Enhancement Program Pilot Grant 
The scientist: Mark Long, PhD
The research: Application of translational multi-omics approaches to derive the features of exceptional response to a novel combination immunotherapy regimen in chemotherapy refractory ovarian cancer

Press release Ovarian Cancer SPORE

The Acquired Resistance to Therapy Network

The National Cancer Institute's Acquired Resistance to Therapy Network (ARTNet) is a collaborative research initiative dedicated to understanding the biological mechanisms that drive resistance to cancer therapies and accelerating the development of strategies to overcome treatment resistance through multidisciplinary, translational research.

As a member of the ARTNet Coordination and Data Management Center (CDMC), Dr. Long collaborates with investigators nationally to develop and apply computational and integrative analytical approaches that support multi-institutional studies of therapeutic resistance. His work focuses on harmonizing and analyzing multi-omic and spatial datasets, facilitating data sharing and collaboration, and advancing translational discoveries that improve cancer treatment outcomes. Dr. Long also serves as Co-Lead of the ARTNet Functional Screens Working Group, helping to coordinate collaborative efforts that integrate functional genomic screening approaches across the network.

ARTNet